Tyra Biosciences (NASDAQ:TYRA) Given New $27.00 Price Target at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA) had its price objective dropped by equities researchers at HC Wainwright from $29.00 to $27.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 28.57% from the company’s previous close.

Several other analysts have also commented on TYRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Thursday, October 15th. William Blair upgraded shares of Tyra Biosciences to a “strong-buy” rating in a research report on Wednesday, September 23rd. Oppenheimer restated an “outperform” rating and issued a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, Wedbush reiterated an “outperform” rating and set a $53.00 price objective on shares of Tyra Biosciences in a research report on Thursday, September 10th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Trading Down 5.8%

NASDAQ:TYRA opened at $21.00 on Wednesday. Tyra Biosciences has a twelve month low of $13.83 and a twelve month high of $40.65. The company has a 50-day moving average of $22.04 and a 200-day moving average of $29.54. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of -8.75 and a beta of 0.65.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07). On average, research analysts forecast that Tyra Biosciences will post -2.68 earnings per share for the current year.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. increased its position in shares of Tyra Biosciences by 31.4% in the third quarter. Alps Advisors Inc. now owns 79,051 shares of the company’s stock worth $1,729,000 after acquiring an additional 18,892 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Tyra Biosciences in the 3rd quarter valued at approximately $67,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Tyra Biosciences by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company’s stock valued at $239,000 after acquiring an additional 1,424 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Tyra Biosciences by 843.4% in the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock worth $27,000 after purchasing an additional 1,088 shares during the period. Finally, Tidal Investments LLC acquired a new position in Tyra Biosciences in the 2nd quarter worth approximately $943,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.